

Amendments to the Claims

Please cancel Claims 5-7. Please amend Claim 8. Please add new Claims 9 and 10. The Claim Listing below will replace all prior versions of the Claims in the application:

Claim Listing

1. (Canceled)
2. (Previously presented) A pharmaceutical composition comprising a unit dosage form of a polydiallylamine homopolymer, said homopolymer characterized in that the polymer is free of alkylated amine monomers, and a pharmaceutically acceptable carrier, wherein said homopolymer is crosslinked by means of a multifunctional crosslinking agent, and said crosslinking agent is present in an amount from about 2.5-20% by weight, based upon the combined weight of monomer and crosslinking agent.
3. (Previously presented) The pharmaceutical composition of Claim 2 wherein the polymer is crosslinked using epichlorohydrin.
4. (Canceled)
5. (Canceled)
6. (Canceled)
7. (Canceled)
8. (Currently amended) A pharmaceutical composition comprising a unit dosage form of a polydiallylamine homopolymer, said homopolymer characterized in that the polymer is free of alkylated amine monomers, and a pharmaceutically acceptable carrier, wherein said homopolymer is crosslinked by means of a multifunctional crosslinking agent, and

said crosslinking agent is present in an amount from about 2.5-20% by weight, based upon the combined weight of monomer and crosslinking agent, The pharmaceutical composition of Claim 2 wherein the unit dosage form is a capsule.

9. (New) The pharmaceutical composition of Claim 2, wherein the polydiallylamine homopolymer is in the free base form.
10. (New) The pharmaceutical composition of Claim 2, wherein the polydiallylamine homopolymer is a salt or partial salt.